Update: Wedbush Raises Travere Therapeutics PT to $19 From $16 After FDA's Approval of Filspari, Keeps Outperform Rating
Update: Wedbush Raises Travere Therapeutics PT to $19 From $16 After FDA's Approval of Filspari, Keeps Outperform Rating
更新：Wedbush將Travere Therapeutics的目標價從$16提高至$19，FDA批准Filspari後，維持跑贏市場評級。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間